We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Software Streamlines, Reduces Costs to Develop and Market Medical Device Technologies

By LabMedica International staff writers
Posted on 30 Apr 2009
Preliminary due diligence and fund development of new medical device technologies can cost up to US$75,000 and take up to three months. More...
But innovators, device manufacturers, service providers, venture capital firms, researchers, healthcare providers, and others now have access to a new online membership community with software that shortens this process to about 90 minutes for only a few thousand dollars, according to the software developer.

E-Zassi (Fernandina, FL, USA) Chief Executive Officer Peter M. von Dyck, remarked, "Not knowing critical details can dramatically hinder a technology from being successfully funded, licensed, developed, or commercialized." These critical details, according to Mr. von Dyck, include: a new technology's probable regulatory classifications; the associated clinical endpoints to support the safety and marketing claims to earn market clearances; early stage clarity on the reimbursement and market landscape; and identification of material manufacturing, distribution, and sales burdens.

E-Zassi dot com is predictive decision-support software that provides rapid due diligence, triaging, and assessment of new medical device innovations. Members can extract critical technical and business-related traits and attributes for a deep analysis and forecast of the opportunities and potential challenges that may be encountered from time of invention throughout all development and commercialization phases. Development and commercially related outputs that are critical include: technology transfer; business development; market and commercial analysis; due diligence and portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants.

All e-Zassi online elements are uniquely categorized and organized among thousands of Device Network Attributes (DNA) the company identified over several years. "We now know how this business and technology 'DNA' can be leveraged by the members in the e-Zassi community to rapidly identify synergistic partners and technologic opportunities," stated Mr. von Dyck. "Empowering our members to leverage these vital attributes on a private online community materially enhances search/match relevancy on a level not available on any other existing network, which helps lower costs, save time, and enhance success rates."

E-Zassi.com is a subscription-based online community and Software as a Service (SaaS) company that was spun off Zassi Medical Evolutions, a privately held company focused on innovation and development in medical devices.

Related Links:

e-Zassi



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: New findings show unique pathogen‑directed antibody patterns are already present years ahead of a formal diagnosis of inflammatory bowel disease (Image Credit: iStock)

Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.